Typhim Vi Injection, Solution
Product Images NDC 49281-790

This text contains a list of components for a syringe, such as the syringe, plunger, syringe cap, syringe tip cap, and barrel. The text may be incomplete or not fully legible, making it difficult to ascertain the context in which these components are being used.*

This is a description of a vaccine called Typhim Vi for the prevention of typhoid fever. The vaccine is manufactured by Sanofi Pasteur SA in Lyon, France, and distributed by Sanofi Pasteur Inc. The dosage is one 0.5mL dose injection for individuals over the age of two, with the injection given at least two weeks prior to travel to endemic or epidemic areas. The vaccine comes in a single-dose prefilled syringe and is administered intramuscularly. The vaccine contains 25ug of purified Vi polysaccharide and is formulated in a buffered solution. The vaccine is stored at 2° to 8°C (35° to 46°F) and should not be frozen. It is important to discard the vaccine if it has been frozen, shows particulate matter, or turbidity.*

This is a description of the Typhim Vi vaccine, which is a multi-dose Polysaccharide vaccine used for IM injections only. The text provides information about the manufacturer and distributor, storage instructions, and a US government license number. The directions for use can be found in the package insert. The product should be stored between 2°C to 8°C and should not be frozen. The cost of the vaccine is £60.*

This is a label of a vaccine named Typhim Vi Polysaccharide Vaccine for Typhoid Vi, manufactured by Sanofi Pasteur SA, which is used for intramuscular administration. The vaccine comes in a single dose of 0.5mL and contains 25g of purified Vi polysaccharide in an isotonic buffered solution. It is recommended to take one dose injection at least two weeks before traveling to endemic or epidemic areas. The vaccine should be stored at 2° to 8°C and should not be frozen. Any vaccine which shows particulate matter of turbidity should be discarded.*